Clinical trials: Drug Interaction Study
Safety
Single Dose and Multiple Dose Escalation Trial of an Oral Formulation of MRX-4
A phase one study of the safety, tolerability, and pharmacokinetics of a new oxazolidinone antibiotic. Cohorts of healthy adults (female and male) will participate in: single dose escalation study of increasing doses of MRX-4…
- Trial name
- NCT03033342
- Testing
- Oral single doses of MRX-4, Oral multiple doses of MRX-4, MRX-4 co-administered with omeprazole
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- MicuRx
T2DM
Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.
This Phase 1 open label study is being conducted to characterize the pharmacokinetic (PK) and safety profiles of Chiglitazar with Empagliflozin，Atorvastatin and Valsartan in healthy subjects.
- Trial name
- NCT05681273
- Testing
- Chiglitazar, Empagliflozin, Atorvastatin
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide
Many patients with type 2 diabetes also have conditions that are treated with diuretics. The patients may also be treated with GSK189075 for their diabetes.
- Trial name
- NCT00671424
- Testing
- Hydrochlorothiazide (HCTZ), Remogliflozin etabonate (GSK189075), Furosemide
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Drug-drug Interaction
Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin
A single-center, open-label, Phase 1, drug-drug interaction study to investigate the effect of voclosporin on the pharmacokinetics of simvastatin and simvastatin acid in healthy volunteers.
- Trial name
- Statin-DDI (NCT05306379)
- Testing
- Simvastatin, Voclosporin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Aurinia Pharmaceuticals Inc.
Pharmacokinetic Interactions
A Preliminary Drug Drug Interaction Study With TA-8995
A study in healthy males to look at how multiple doses of TA-8995 affect blood levels and rate of removal of other drugs, using single doses of digoxin and midazolam as examples, to see if there are any potential drug…
- Trial name
- NCT02124954
- Testing
- TA-8995, Midazolam, Digoxin
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Xention Ltd
Hypertension, Diabetes Mellitus, Type 2
A Clinical Trial Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1019-1 and BR1019-2 in Healthy Adult Subjects
The purpose of this study is to evaluate the pharmacokinetic interaction and safety between BR1019-1 and BR1019-2 in healthy adult subjects.
- Trial name
- NCT05875259
- Testing
- BR1019-1, BR1019-2, BR1019-1 + BR1019-2
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Healthy
Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants
This is a 2-part, open label, fixed-sequence study to evaluate the potential drug interaction between ALXN2050 and fluconazole (Part 1), and between ALXN2050 and rifampin (Part 2) in healthy adult participants.
- Trial name
- NCT04933682
- Testing
- ALXN2050, Fluconazole, Rifampin
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hepatitis C, Hypertension
A Drug Interaction Study of Boceprevir in Combination With Amlodipine or Diltiazem in Healthy Volunteers
The purpose of this study is to evaluate the pharmacokinetic interactions between the hepatitis C NS3 protease inhibitor boceprevir and the calcium channel blockers amlodipine and diltiazem in healthy volunteers.
- Trial name
- NCT01549496
- Testing
- Amlodipine, Diltiazem
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Ottawa Hospital Research Institute
Drug Drug Interaction
Fruquintinib CYP3A Inhibitor and Inducer Study
A study to assess the effect of itraconazole, a strong CYP3A inhibitor, and the effect of rifampin, a strong CYP3A inducer, on the pharmacokinetics of fruquintinib in healthy subjects.
- Trial name
- NCT04557397
- Testing
- Fruquintinib, Itraconazole, Rifampin
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hutchison Medipharma Limited
Healthy, NAFLD
DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.
The primary objective of this study is to evaluate the effect of itraconazole, a strong inhibitor)of cytochrome P4503A , and phenytoin a strong inducer of cytochrome P450 3A, CYP3A4, CYP1A2 and CYP2C19 on the pharmacokinetics of…
- Trial name
- NCT04845646
- Testing
- ASC41, Itraconazole, Phenytoin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Healthy
Drug Transporter Interaction Study PHENTRA_2015_KPUK
The objective of the present study is to contribute to establishing in vivo phenotyping procedures for organic anionic transporter polypeptide 1B1 (OATP1B1), organic cation transporters 1 and 2 (OCT1/2), multidrug and toxic…
- Trial name
- NCT02743260
- Testing
- pitavastatin, Metformin, digoxin
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Cologne
Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body
This study will be an open-label, fixed sequence study in healthy subjects (vasectomized males and females of non-childbearing potential), performed at a single study centre.
- Trial name
- NCT04712396
- Testing
- Capivasertib, Itraconazole
- Where
- Germany
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Mitochondrial Disease
Drug-drug Interaction Study of KL1333 in Healthy Subjects
A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects
- Trial name
- NCT04643249
- Testing
- KL1333, Flurbiprofen, Dextromethorphan
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Abliva AB
HIV Infections
Drug Interaction Study With Proton Pump Inhibitor
The purpose of this clinical research study is to assess the effect of omeprazole at 20 mg on the pharmacokinetics of atazanavir administered as atazanavir with ritonavir relative to atazanavir or atazanavir/ritonavir in the…
- Trial name
- NCT00357240
- Testing
- Atazanavir, Atazanavir/Ritonavir, Atazanavir/Ritonavir+Omeprazole
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteers
A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults
The main aim of this study is to find out how zasocitinib (TAK-279) interacts with other medicines taken by mouth (orally). This will be examined by how the body processes medicines, which is called pharmacokinetics or PK.
- Trial name
- NCT06793943
- Testing
- Zasocitinib, COC, Metformin
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Takeda
Pharmacokinetics, Cytochrome P-450 CYP2D6
Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects
The goal of this study is to evaluate the effect of multiple doses of Desvenlafaxine Sustained Release (SR) on the pharmacokinetics of Aripiprazole when coadministered to healthy adult subjects.
- Conditions
- Pharmacokinetics, Cytochrome P-450 CYP2D6, CYP3A4 Protein, Human
- Trial name
- NCT01188668
- Testing
- Aripiprazole, Aripiprazole + desvenlafaxine succinate sustained release
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteer
GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir
The purpose of this study is to compare the amount of GSK1349572 (study drug) in the blood when given with and without atazanavir/ritonavir or atazanavir and to compare the blood levels of atazanavir when given with GSK1349572 to…
- Trial name
- NCT00883935
- Testing
- GSK1349572, Atazanavir 300 mg, Atazanavir 400 mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
Drug-Drug Interaction Study of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy Participants
This is a phase 1, open-label, fixed-sequence, 2-period drug-drug interaction study to evaluate the pharmacokinetic interactions of itraconazole, rifampicin, midazolam, and SIM0417/ritonavir in healthy Chinese subjects.
- Trial name
- NCT05665647
- Testing
- Cohort 1: SIM0417/ritonavir and itraconazole, Cohort 2: SIM0417/ritonavir and rifampicin, Cohort 3: SIM0417/ritonavir and midazolam
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Healthy Participants
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
This study consists of 3 parts: Part A, Part B and Part C. This study will compare the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD4144 with placebo in healthy participants, in Part A and Part B.
- Trial name
- NCT06491550
- Testing
- AZD4144- Part A, AZD4144- Part B, Rosuvastatin and Furosemide- Part C
- Where
- 2 sites in United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Latent Tuberculosis, Human Immunodeficiency Virus
Doravirine, Rifapentine and Isoniazid Interaction
Drug therapy for persons living with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) co-infected with latent tuberculosis infection (LTBI) is complex.
- Conditions
- Latent Tuberculosis, Human Immunodeficiency Virus, Rifamycins Causing Adverse Effects in Therapeutic Use, Drug Interaction Potentiation
- Trial name
- DORIIS (NCT03886701)
- Testing
- Doravirine (DOR), Rifapentine (RPT), Isoniazid (INH)
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Walter K. Kraft
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.